BANK VONTOBEL/PUT/BIOGEN IDEC/240/0.01/21.06.24 | Delayed Deutsche Boerse AG 12:52:39 03/06/2024 BST | ||
| 0.149 EUR | -6.29% |
|
| 1 month | -30.26% | ||
| 3 months | -28.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 0.149 | -6.29% |
| 31/05/24 | 0.159 | -22.82% |
| 30/05/24 | 0.206 | -11.59% |
| 29/05/24 | 0.233 | +8.37% |
| 28/05/24 | 0.215 | +4.37% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 12:52 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU9CS6 |
| ISIN | DE000VU9CS63 |
| Date issued | 03/07/2023 |
| Strike | 240 $ |
| Maturity | 21/06/2024 (18 Days) |
| Parity | 100 : 1 |
| Emission price | 0.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.47 € |
|---|---|
| Lowest since issue | 0.091 € |
| Spread | 0.01 € |
| Spread % | 6.37% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Warrants
- Warrant
